DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQure™)

PR Newswire
June 10, 2024 — 13:14 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: California Education healthcare South Korea Stanford technology University

Related News:

Cybellum Receives Frost & Sullivan’s Competitive Strategy Award for its Innovative Product Security Solutions

September 27, 2024 — 01:00

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Hyundai Motor Group Companies’ Ratings Upgraded by Global Top Rating Agencies

August 26, 2024 — 17:24

WSPN Appoints Ex-Visa President John Partridge as Board Director

August 22, 2024 — 11:22

Docquity and Vietnam Association of Preventive Medicine (VAPM) Partner to Advance Medical Training

August 21, 2024 — 10:00

Midea Group Reports a Record-Breaking RMB 20 Billion in H1 Profits

August 20, 2024 — 11:49

Franchising and Licensing Asia (FLAsia) 2024